Department of Surgery, Section of Otolaryngology, Yale University School of Medicine, New Haven, Connecticut, U.S.A.
Yale Cancer Center, New Haven, Connecticut, U.S.A.
Laryngoscope. 2019 Nov;129(11):2496-2505. doi: 10.1002/lary.27785. Epub 2019 Jan 10.
To analyze the incidence and clinical profile of nonsquamous cell (non-SCC) laryngeal carcinomas and to analyze the effect of surgery on survival.
A retrospective analysis of the National Cancer Database (2004-2014).
Adult patients with non-SCC laryngeal cancers were divided into six major histological subtypes. A descriptive clinical profile was obtained for non-SCC patients, and multivariate regressions were performed to analyze the effect of surgery on survival within the non-SCC cohort.
We identified 878 cases of non-SCC laryngeal cancers, representing 1.02% of all malignant laryngeal cancers. Neuroendocrine tumors and bone/cartilage sarcomas made up the largest groups (37.02% and 32.35%, respectively). Metastasis (M) was higher in neuroendocrine tumors, representing 19.1% of those with known clinical M stages. Of those treated, the majority of patients with bone/cartilage sarcomas (80.9%) and minor salivary gland tumors (82.6%) received surgery as part of their treatment. Survival varied significantly based upon histology, with bone/cartilage sarcomas having the highest 5-year survival at 90.4%, and neuroendocrine tumors exhibiting the poorest 5-year survival at 25.7%. Multivariate analyses found surgery to be significantly associated with improved survival (hazard ratio: 0.679; 95% confidence interval: 0.472-0.976; P = 0.036). The specific surgical method (i.e., local excision vs. partial vs. total laryngectomy) did not have any effect on survival.
Approximately 1% of all malignant laryngeal cancers are non-SCC in origin. At presentation, neuroendocrine tumors have the highest rate of distant metastasis and have the worst prognosis of the non-SCC cancers. Most non-SCC patients received surgery as part of their treatment regimen.
NA. Laryngoscope, 129:2496-2505, 2019.
分析非鳞状细胞(非 SCC)喉癌的发病率和临床特征,并分析手术对生存率的影响。
国家癌症数据库(2004-2014 年)的回顾性分析。
将非 SCC 喉癌患者分为六大主要组织学亚型。对非 SCC 患者进行描述性临床特征分析,并在非 SCC 队列中进行多变量回归分析手术对生存率的影响。
我们共发现 878 例非 SCC 喉癌,占所有恶性喉癌的 1.02%。神经内分泌肿瘤和骨/软骨肉瘤占比最大(分别为 37.02%和 32.35%)。神经内分泌肿瘤的转移(M)率更高,已知临床 M 期患者中占 19.1%。在接受治疗的患者中,大部分骨/软骨肉瘤(80.9%)和小唾液腺癌(82.6%)患者接受了手术作为治疗的一部分。生存率因组织学而异,骨/软骨肉瘤的 5 年生存率最高,为 90.4%,神经内分泌肿瘤的 5 年生存率最低,为 25.7%。多变量分析发现手术与生存率显著相关(风险比:0.679;95%置信区间:0.472-0.976;P=0.036)。具体的手术方法(即局部切除与部分与全喉切除术)对生存率没有影响。
大约 1%的恶性喉癌是非 SCC 起源的。在发病时,神经内分泌肿瘤具有最高的远处转移率,并且是非 SCC 癌症中预后最差的。大多数非 SCC 患者接受了手术作为其治疗方案的一部分。
NA。《喉镜》,129:2496-2505,2019。